Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
PYC Therapeutics Limited ( (AU:PYC) ) has provided an announcement.
PYC Therapeutics Limited has announced its Annual General Meeting will be held on November 18, 2025, at the Harry Perkins Institute of Medical Research in Western Australia. This meeting is significant for stakeholders as it provides insights into the company’s strategic direction and operational updates, reinforcing its commitment to advancing RNA therapies in the biotechnology sector.
The most recent analyst rating on (AU:PYC) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
More about PYC Therapeutics Limited
PYC Therapeutics is a clinical-stage biotechnology company focused on developing RNA therapies for genetic diseases. They leverage a proprietary drug delivery platform to enhance the effectiveness of precision medicines, specifically targeting monogenic diseases which have a higher likelihood of success in clinical trials.
Average Trading Volume: 771,808
Technical Sentiment Signal: Buy
Current Market Cap: A$711.6M
For a thorough assessment of PYC stock, go to TipRanks’ Stock Analysis page.